BioCryst Pharmaceuticals | BCRX - Debt


BioCryst Pharmaceuticals reported $828.6M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Chugai Pharma JPY 14.11B 1.93B Dec/2022
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
DBV Technologies USD 6.1M 2.49M Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novavax USD 233.31M 4.23M Sep/2024
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026